Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.74 |
| ▸ | MEN1 | O00255 | 4/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.74 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.74 |
| ▸ | MPO | P05164 | 2/20 | 0.74 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.74 |
| ▸ | LMNA | P02545 | 2/20 | 0.74 |
| ▸ | TSHR | P16473 | 2/20 | 0.74 |
| ▸ | BLM | P54132 | 2/20 | 0.74 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.74 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | APAF1 | O14727 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | RECQL | P46063 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1769607 | 1.00 | MAPT (0.74) | MAPTMEN1KMT2AKDM4EMPO | |
| SCHEMBL1769610 | 1.00 | MAPT (0.74) | MAPTMEN1KMT2AKDM4EMPO | |
| SCHEMBL27426182 | 1.00 | MAPT (0.74) | MAPTMEN1KMT2AKDM4EMPO | |
| SCHEMBL17704081 | 0.92 | KDM4E (0.70) | MAPTMEN1KMT2AKDM4EMPO | |
| SCHEMBL23897642 | 0.87 | MAPT (0.59) | MAPTMEN1KMT2AKDM4EMPO | |
| SCHEMBL26428319 | 0.86 | HTR2A (0.60) | MAPTMEN1KMT2AKDM4EMPO | |
| SCHEMBL23762398 | 0.86 | HTR2A (0.60) | MAPTMEN1KMT2AKDM4EMPO | |
| Tryptophan SCHEMBL4732053 | 0.85 | KMT2A (1.00) | MAPTMEN1KMT2AKDM4EMPO | |
| Dl-Tryptophan SCHEMBL475349 | 0.85 | KMT2A (1.00) | MAPTMEN1KMT2AKDM4EMPO | |
| Tryptophan SCHEMBL23141133 | 0.85 | KMT2A (1.00) | MAPTMEN1KMT2AKDM4EMPO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 315 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12600699-B2 | Thiosemicarbazates and uses thereof | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2026-04-14 | — | — | US | claimed |
| EP-4720087-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR | Zealand Pharma A/S (DK) | 2026-04-08 | — | — | EP | claimed |
| US-20250027949-A1 | EVALUATING METHOD FOR RELATIVE PHARMACOLOGICAL ACTIONS OF COMBINATIONS OF IMMUNE CHECKPOINT INHIBITORS AND ANTICANCER DRUGS AS COMBINATION DRUGS COMPARED WITH PHARMACOLOGICAL ACTIONS OF IMMUNE CHECKPOINT INHIBITORS ALONE, CALCULATING METHOD, EVALUATING APPARATUS, CALCULATING APPARATUS, EVALUATING PROGRAM, CALCULATING PROGRAM, RECORDING MEDIUM, EVALUATING SYSTEM, AND TERMINAL APPARATUS | AJINOMOTO CO., INC. (JP) | 2025-01-23 | — | — | US | claimed |
| WO-2024246269-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR | ZEALAND PHARMA A/S (DK) | 2024-12-05 | — | — | WO | claimed |
| EP-4471048-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR | Zealand Pharma A/S (DK) | 2024-12-04 | — | — | EP | claimed |
| EP-4471049-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR | Zealand Pharma A/S (DK) | 2024-12-04 | — | — | EP | claimed |
| WO-2023195447-A1 | EVALUATION METHOD, CALCULATION METHOD, EVALUATION DEVICE, CALCULATION DEVICE, EVALUATION PROGRAM, CALCULATION PROGRAM, RECORDING MEDIUM, EVALUATION SYSTEM AND TERMINAL DEVICE FOR RELATIVE PHARMACOLOGICAL ACTION OF COMBINATION OF IMMUNE CHECKPOINT INHIBITOR WITH ANTICANCER DRUG AS CONCOMITANT DRUG COMPARED TO PHARMACOLOGICAL ACTION OF IMMUNE CHECKPOINT INHIBITOR ALONE | 味の素株式会社 | 2023-10-12 | — | — | WO | claimed |
| US-11753443-B2 | Conjugated hepcidin mimetics | PROTAGONIST THERAPEUTICS, INC. (US) | 2023-09-12 | — | — | US | claimed |
| EP-4237427-A1 | ANTIBACTERIAL CYCLOPEPTIDES TARGETING ACINETOBACTER AND OTHER GRAM-NEGATIVE PATHOGENS | University of Utah Research Foundation (US) | 2023-09-06 | — | — | EP | claimed |
| CN-116670151-A | Antibacterial cyclic peptides targeting acinetobacter and other gram negative pathogens | 犹他大学研究基金会 | 2023-08-29 | — | — | CN | claimed |
| EP-4188412-A1 | CONJUGATED HEPCIDIN MIMETICS | Protagonist Therapeutics, Inc. (US) | 2023-06-07 | — | — | EP | claimed |
| CN-116178506-A | Stapler peptide and application thereof | 湖南中晟全肽生化有限公司 | 2023-05-30 | — | — | CN | claimed |
| US-20230111252-A1 | THIOSEMICARBAZATES AND USES THEREOF | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2023-04-13 | — | — | US | claimed |
| WO-2022234972-A1 | ANTIMICROBIAL PEPTOID HAVING IMPROVED SELECTIVITY AND ANTIMICROBIAL COMPOSITION COMPRISING SAME | 광주과학기술원 | 2022-11-10 | — | — | WO | claimed |
| US-20220268790-A1 | EVALUATING METHOD FOR PHARMACOLOGICAL ACTIONS OF IMMUNE CHECKPOINT INHIBITORS, CALCULATING METHOD, EVALUATING APPARATUS, CALCULATING APPARATUS, EVALUATING PROGRAM, CALCULATING PROGRAM, RECORDING MEDIUM, EVALUATING SYSTEM, AND TERMINAL APPARATUS | AJINOMOTO CO., INC. (JP) | 2022-08-25 | — | — | US | claimed |
| WO-2022094273-A1 | ANTIBACTERIAL CYCLOPEPTIDES TARGETING ACINETOBACTER AND OTHER GRAM-NEGATIVE PATHOGENS | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2022-05-05 | — | — | WO | claimed |
| WO-2022026631-A1 | CONJUGATED HEPCIDIN MIMETICS | PROTAGONIST THERAPEUTICS, INC. (US) | 2022-02-03 | — | — | WO | claimed |
| US-12612605-B2 | Carboxyesterase polypeptides for kinetic resolution | CODEXIS, INC. (US) | 2026-04-28 | — | — | US | disclosed |
| WO-2022025204-A1 | TREATMENT OF DISEASE WITH EPOR ANTAGONIST | エポメッド株式会社 | 2022-02-03 | — | — | WO | disclosed |
| WO-2022026631-A1 | CONJUGATED HEPCIDIN MIMETICS | PROTAGONIST THERAPEUTICS, INC. (US) | 2022-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11753443-B2 | Conjugated hepcidin mimetics | HAMP, VIP, HDGF | MAPT 4733/4885MEN1 277/4885KMT2A 3691/4885 |
| US-20230111252-A1 | THIOSEMICARBAZATES AND USES THEREOF | TST, ABAT, AADAC | MAPT 1493/4885MEN1 850/4885KMT2A 1523/4885 |
| US-12612605-B2 | Carboxyesterase polypeptides for kinetic resolution | CES1, CPA1, RNGTT | MAPT 4855/4885MEN1 3279/4885KMT2A 1665/4885 |
| US-12600699-B2 | Thiosemicarbazates and uses thereof | MET, THRB, ABAT | MAPT 1679/4885MEN1 1699/4885KMT2A 2188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.